Political Liason Joins BioSig Technologies Advisory Board

BioSig Technologies Inc., a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the electrophysiology (EP) marketplace, announced that Frank J. Quintero, a Los Angeles-based investor, joined the company’s Advisory Board.  

Quintero is a principal at The Yucaipa Companies, an investment firm founded by Ron Burkle in 1986. His responsibilities as a principal of the firm encompass deal origination, negotiating transactions, investor relations and corporate communications. Working closely with The Yucaipa Companies’ founder, Quintero actively participated in multiple phases of the investment process since joining the firm. The Yucaipa Companies has completed mergers and acquisitions valued at more than $35 billion.
 
Prior to joining The Yucaipa Companies, Quintero served as special assistant to former California Gov. Gray Davis. In this position he served as a liaison to labor officials and business groups; as well as local, state, and national elected officials. Quintero was also an advisor to Davis on over 300 boards and commission appointments within the California state government. Under Governor Davis’ leadership the Appointments Unit placed more women and people of color in appointed positions than any of California’s previous governors.  
 
Active in numerous statewide and local political campaigns, in 1998 Quintero worked as State Field Director for the California Democratic Party Coordinated Campaign. As part of the three-person team managing a budget of several million dollars, Quintero directed over 30 offices throughout the state and oversaw print, radio, and direct mail advertising. His efforts on behalf of the Coordinated Campaign’s “Get-Out-The-Vote” drive produced record voter registration and turnout in low-income communities.
 
Based on his experience unifying divergent groups, Quintero was chosen as one of 60 Americans to receive a Marshall Fellowship in 2001. He became part of a team of scholars and government officials brought together to advise European Union member nations, NGOs, and the head of NATO on economic integration and immigration policy.

“Frank brings to us very impressive track record in investment, government and communications sectors. We are confident that Frank’s many achievements and his strong relationships in the state of California will be a definite advantage to our growing operations,” commented Kenneth L. Londoner, chairman and CEO of BioSig Technologies Inc.

The goal of the Advisory Board is to advise the leadership of BioSig on a range of subjects, including financing, strategy, marketing, government affairs, partnerships and M&A. Current board members include Los Angeles-based political advisor and business leader Sim Farar; San Francisco Bay area-based Kent Bennett Williams, CEO and Principal at Vista Asset Management LLC; Texas-based Dr. Ramachandra Malya, medical director; and Los Angeles based investor, recording artist and songwriter D.A. Wallach.

“I have been impressed by BioSig’s innovative thinking and their dedication to advance medicine through novel technological solutions. I look forward to working with the management and contribute my expertise to enhance the company’s growth,” commented Quintero.

BioSig Technologies is a medical technology company developing a proprietary biomedical signal processing platform designed to improve the electrophysiology (EP) marketplace. Led by a management team and a veteran, independent Board of Directors, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP System. The technology has been developed to address an unmet need in a large and growing market. The PURE EP System is a cardiac signal acquisition and display system that is engineered to assist electrophysiologists in clinical decision-making during procedures to diagnose and treat patients with abnormal heart rates and rhythms. BioSig’s main goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias, atrial fibrillation and ventricular tachycardia. BioSig has partnered with Minnetronix on technology development and received U.S. Food and Drug Administration 510(k) clearance for the PURE EP System in August 2018.